Clinical trial · Observational
Correlation Between the Analgesic Effect of Fentanyl Transdermal Patches and Nutritional Status in Cancer Pain Patients
A Retrospective Clinical Study on the Impact of Nutritional Status on the Analgesic Effect of Fentanyl Transdermal Patches in Cancer Pain Patients
NCT06369961CI-TRIAL-00076180completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to investigate the correlation and quantitative relationship between the analgesic effect of fentanyl transdermal patches in cancer pain patients and their nutritional status.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Pain | — | UNRESOLVED | — |
| Nutrition Disorders | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| transdermal fentanyl | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Group A
- description
- Those who used TDF
- interventionNames
- Drug: transdermal fentanyl
Primary outcomes (4)
- measure
- 11-point numeric rating scale (NRS) after TDF treatment
- timeFrame
- in 1 week
- description
- Ineffectiveness defined as pain with a NRS of 4 or higher.
- measure
- the occasions that breakthrough pain attacks per day after TDF treatment
- timeFrame
- in 1 week
- description
- Ineffectiveness defined as the breakthrough pain attacks more than 3 occasions per day
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Cancer pain patients admitted to our hospital; * Cancer pain patients switched from oral sustained-release strong opioid analgesics to fentanyl transdermal patches during the hospital stay. Exclusion Criteria: * Patients who have been switched to fentanyl transdermal patches after titration with an analgesic pump; * Patients using fentanyl transdermal patches in combination with other oral sustained-release strong opioid analgesics; * Patients using fentanyl transdermal patches in combination with an analgesic pump; * Patients who have used fentanyl transdermal patches for less than 3 days; * Patients with postoperative pain; * Patients with allergies; * Patients who are pregnant women; * Patients with missing data.
References
Publications (4)
- RESULTMinello C, George B, Allano G, Maindet C, Burnod A, Lemaire A. Assessing cancer pain-the first step toward improving patients' quality of life. Support Care Cancer. 2019 Aug;27(8):3095-3104. doi: 10.1007/s00520-019-04825-x. Epub 2019 May 11. PMID 31076899
- RESULTBarratt DT, Bandak B, Klepstad P, Dale O, Kaasa S, Christrup LL, Tuke J, Somogyi AA. Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. Pharmacogenet Genomics. 2014 Apr;24(4):185-94. doi: 10.1097/FPC.0000000000000032. PMID 24469018
- RESULTMoryl N, Bokhari A, Griffo Y, Hadler R, Koranteng L, Filkins A, Zheng T, Horn SD, Inturrisi CE. Does transdermal fentanyl work in patients with low BMI? Patient-reported outcomes of pain and percent pain relief in cancer patients on transdermal fentanyl. Cancer Med. 2019 Dec;8(18):7516-7522. doi: 10.1002/cam4.2479. Epub 2019 Sep 30. PMID 31568684
- DERIVEDChen Y, Han S, Hu X, Ma X, Qiu Y, Tang Y, Wang X, Li L, Li C, Chen W. High BMI predicts poor cancer pain relief when rotating from oral opioids to transdermal Fentanyl: a two-center retrospective study. Pharmacol Rep. 2025 Jun;77(3):789-799. doi: 10.1007/s43440-025-00723-8. Epub 2025 Apr 11. PMID 40214947